Alice Dawson, Lindsay B Tulloch, Keri L Barrack, William N Hunter
Index: Acta Crystallogr. D Biol. Crystallogr. 66(Pt 12) , 1334-40, (2010)
Full Text: HTML
Pteridine reductase (PTR1) is a potential target for drug development against parasitic Trypanosoma and Leishmania species. These protozoa cause serious diseases for which current therapies are inadequate. High-resolution structures have been determined, using data between 1.6 and 1.1 Å resolution, of T. brucei PTR1 in complex with pemetrexed, trimetrexate, cyromazine and a 2,4-diaminopyrimidine derivative. The structures provide insight into the interactions formed by new molecular entities in the enzyme active site with ligands that represent lead compounds for structure-based inhibitor development and to support early-stage drug discovery.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Cyromazine
CAS:66215-27-8 |
C6H10N6 |
Validation of a rapid method of analysis using ultrahigh-per...
2014-12-19 [J. Chromatogr. A. 1373 , 106-13, (2014)] |
Inheritance mode, cross-resistance and realized heritability...
2015-02-01 [Acta Trop. 142 , 149-55, (2014)] |
A novel colloidal gold-based lateral flow immunoassay for ra...
2013-06-01 [Food Chem. 138(2-3) , 1610-5, (2013)] |
A liquid chromatography-tandem mass spectrometry method for ...
2012-01-13 [J. Chromatogr. A. 1220 , 101-7, (2012)] |
Species displacements are common to two invasive species of ...
2011-12-01 [J. Econ. Entomol. 104(6) , 1771-3, (2011)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved